EGFR and head and neck squamous cell carcinoma: Moreover, ML324 and GSK-J4 synergistically increased the pro-apoptotic activity of EGFR or PI3K signaling inhibitors—erlotinib or HS-173, respectively—in HNSCC cells [17].